Articlenpj drug discovery2026
Deep learning-driven integrated pipeline for de novo design and synthesis of antimicrobial peptides.
Article in npj drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Antimicrobial peptides (AMPs) are promising alternatives to conventional antibiotics against bacterial infections. However, the discovery of AMPs is impeded by the limitations of biochemical screening and the difficulty computational approaches face in balancing efficacy with structural diversity. We proposed an integrated "generation-evaluation-validation" framework to facilitate de novo discovery of AMPs. First, we constructed a soft prompt-tuned ProtGPT2 to efficiently generate candidates AMPs with both novel structures and promising therapeutic potential. Secondly, we adopted a multiple-choice learning ensemble model that enables high-confidence evaluation of candidates via a dynamic voting network. Finally, antimicrobial experiments were used to validate the activity of top-ranked de novo AMPs by monitoring bacterial surface changes. Out of nine candidates, four exhibited potent strain-specific activity, while two demonstrated broad-spectrum efficacy. All tested AMPs exhibited strong biofilm inhibition, potent membrane disruption, and minimal hemolysis, indicating significant therapeutic potential. With strong generalizability and versatility beyond AMPs, the proposed framework's modular design will facilitate adaptation to diverse peptide design tasks in the future. By integrating soft prompt tuning, multimodal ensemble learning, and experimental verification, this framework presents a practical and scalable strategy for rapid, resource-efficient de novo peptide discovery, particularly suited for applications where experimental throughput and cost are critical constraints.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.